Chan Lee, Seongjae Kim, Jinseon You, Minjeong Seo, Youngbin Kim, Jeongdon Park, Hye-Won Park, Jaerang Rho
{"title":"Cholera toxin B subunit fusion enhances the immunogenicity of the H5 stem domain against the H5N2 avian influenza virus.","authors":"Chan Lee, Seongjae Kim, Jinseon You, Minjeong Seo, Youngbin Kim, Jeongdon Park, Hye-Won Park, Jaerang Rho","doi":"10.7774/cevr.2025.14.e41","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The development of a universal avian influenza vaccine remains a critical issue for both the global public health and poultry industries. The hemagglutinin (H) stem/stalk region of highly pathogenic avian influenza viruses (HPAIVs) is capable of inducing broadly neutralizing antibodies but is limited by its poor immunogenicity.</p><p><strong>Materials and methods: </strong>To increase the immunogenicity of the stem domain, we engineered a recombinant fusion construct consisting of the stem domain of the H5 subtype and the nontoxic cholera toxin B subunit (CTB), a well-characterized mucosal adjuvant and immunomodulator. C57BL/6 mice were immunized intraperitoneally with the CTB-H5 stem fusion protein. Humoral immune responses and virus-neutralizing activities were subsequently assessed.</p><p><strong>Results: </strong>Mice immunized with CTB-H5 stem fusion protein developed significantly higher serum immunoglobulin G titers and increased binding affinity to the native trimeric H5 antigen. Sera from the CTB-H5 stem group demonstrated enhanced virus-neutralizing activity in plaque reduction assays against the H5N2 virus. These results suggest that CTB fusion significantly enhances the immunogenicity and protective potential of the conserved H5 stem domain against the H5N2 virus.</p><p><strong>Conclusion: </strong>These findings support the use of CTB as an effective adjuvant platform for the development of stem-based influenza vaccines targeting HPAIVs.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 4","pages":"385-393"},"PeriodicalIF":1.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12599431/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The development of a universal avian influenza vaccine remains a critical issue for both the global public health and poultry industries. The hemagglutinin (H) stem/stalk region of highly pathogenic avian influenza viruses (HPAIVs) is capable of inducing broadly neutralizing antibodies but is limited by its poor immunogenicity.
Materials and methods: To increase the immunogenicity of the stem domain, we engineered a recombinant fusion construct consisting of the stem domain of the H5 subtype and the nontoxic cholera toxin B subunit (CTB), a well-characterized mucosal adjuvant and immunomodulator. C57BL/6 mice were immunized intraperitoneally with the CTB-H5 stem fusion protein. Humoral immune responses and virus-neutralizing activities were subsequently assessed.
Results: Mice immunized with CTB-H5 stem fusion protein developed significantly higher serum immunoglobulin G titers and increased binding affinity to the native trimeric H5 antigen. Sera from the CTB-H5 stem group demonstrated enhanced virus-neutralizing activity in plaque reduction assays against the H5N2 virus. These results suggest that CTB fusion significantly enhances the immunogenicity and protective potential of the conserved H5 stem domain against the H5N2 virus.
Conclusion: These findings support the use of CTB as an effective adjuvant platform for the development of stem-based influenza vaccines targeting HPAIVs.
期刊介绍:
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide